Poor outcomes for trial-ineligible patients receiving polatuzumab for relapsed/refractory diffuse large B-cell lymphoma in routine care: An Australian Lymphoma and Related Diseases Registry project.
Shaw B, Chung E, Wellard C, Yoo E, Bennett R, Birks C, Johnston A, Cheah CY, Hamad N, Simpson J, Barraclough A, Ku M, Viiala N, Ratnasingam S, Armytage T, Cochrane T, Chong G, Lee D, Manos K, Keane C, Wallwork S, Opat S, Hawkes EA.
Shaw B, et al. Among authors: wallwork s.
EJHaem. 2024 Feb 23;5(2):325-332. doi: 10.1002/jha2.870. eCollection 2024 Apr.
EJHaem. 2024.
PMID: 38633125
Free PMC article.